16. Mediastinitis & Deep Sternal Wound Infection

Quick Recap

Cardiac Surgery Critical Care, Protocol 16 (final protocol in this section). Addresses the most feared infectious complication after cardiac surgery — with a genuinely important, honest contrast between negative pressure wound therapy's well-supported role in TREATING established infection versus its considerably less certain, possibly even counterproductive role in PREVENTING it in the first place.

1. Definition

Deep sternal wound infection (DSWI), also known as mediastinitis, may result from open cardiac surgery itself or from descending necrotizing mediastinitis of a different primary source. Diagnosis (per CDC criteria) requires at least one of: positive mediastinal tissue/fluid culture, surgical or histopathological evidence of mediastinitis, or clinical signs (fever, chest pain, sternal instability) accompanied by purulent mediastinal discharge, positive blood/discharge cultures, or mediastinal widening on imaging.

DSWI carries a still-relevant incidence despite decades of preventive advances, with considerable impact on in-hospital mortality and also on mid- and long-term survival — a meta-analysis specifically found DSWI associated with higher mortality, stroke, MI, and respiratory/renal failure, extending well beyond the acute infectious episode itself.

2. Risk Factors

Well-established risk factors: obesity, diabetes mellitus, COPD, bilateral internal mammary artery (IMA) harvest, immunodeficiency, corticosteroid therapy, reoperation, chest radiotherapy, and dialysis-dependent renal failure. In one high-risk cohort, diabetes and obesity were each present in over 80% of enrolled patients — illustrating how concentrated in a specific comorbidity profile this risk really is, useful for identifying which patients warrant the most aggressive preventive attention.

3. A Genuinely Important, Honest Contrast — Treatment vs. Prevention

NPWT for TREATING Established DSWI — Well-Supported

A systematic review/meta-analysis of NPWT (vacuum-assisted closure) for established deep sternal wound infection found NPWT significantly reduces mortality and reinfection rates compared to conventional wound management, alongside significantly shorter hospital and ICU stay. This is a genuinely well-supported use case, consistent across multiple studies including direct comparisons finding topical negative pressure superior to closed irrigation therapy for established DSWI.

NPWT for PREVENTING Sternal Wound Infection — Genuinely Uncertain, Possibly Counterproductive

A 2025 propensity-matched study of closed-incision NPWT (ciNPWT) used PROPHYLACTICALLY in high-risk CABG patients found the ciNPWT group had a SIGNIFICANTLY HIGHER rate of sternal wound infection than the conventional-dressing control group (25.4% vs. 9.9%, p=0.03) — a genuinely striking, counterintuitive finding directly contradicting the intuitive assumption that a technology proven to help treat established infection would also help prevent it. A separate prophylactic NPWT study (Prevena device, high-risk patients) found no significant difference in wound complications versus control (10% vs. 17.5%, p=0.52) — underpowered, but trending in the same direction as "no clear prophylactic benefit," not confirming the intuitive preventive rationale.

This protocol treats prophylactic NPWT as a genuinely unresolved, and possibly counterproductive, intervention — distinctly different from its well-supported therapeutic role once infection is already established. Do not assume that a device effective for treating DSWI is automatically effective for preventing it — this is precisely the kind of surrogate-mechanism-to-clinical-outcome assumption this library treats with consistent skepticism elsewhere (cross-reference Postoperative Atrial Fibrillation Prophylaxis's PALACS discussion, Cardiovascular System, for the same underlying caution applied to a different intervention).

A Real, Specific Safety Concern with NPWT

The most frequently reported NPWT complications include right ventricular rupture and major bleeding events — a genuinely serious, specific risk reflecting the device's proximity to the heart and great vessels in this particular anatomic location, unlike NPWT use elsewhere on the body. Adherence to protective measures and guidelines during therapy is essential to mitigate this risk — this is not a generic wound-care device being applied to a generic wound.

4. Practical Synthesis

• For established DSWI: NPWT is a well-supported treatment modality, reducing mortality, reinfection, and length of stay compared to conventional wound management
• For prevention in high-risk patients: do NOT assume NPWT provides a preventive benefit analogous to its treatment benefit — current evidence is genuinely mixed-to-negative, with one study showing a signal of harm
• Actively identify and address modifiable risk factors (glycemic control, smoking cessation where feasible, minimizing unnecessary reoperation) as the more evidence-grounded prevention strategy, rather than defaulting to a specific device
• When using NPWT in the sternal location specifically, maintain heightened vigilance for right ventricular rupture and major bleeding — a genuinely different risk profile from NPWT use on other body regions

5. Consultation Matrix

6. Documentation & Medicolegal Checklist

• Risk factor profile documented preoperatively to inform individualized prevention discussion
• Rationale for prophylactic NPWT use (if chosen) documented, given the genuinely uncertain evidence base for this specific indication
• NPWT monitoring for RV rupture/bleeding risk documented per institutional protocol

7. Key Guidelines

• No single guideline mandates prophylactic NPWT given the genuinely mixed evidence; therapeutic NPWT for established DSWI has broader support across multiple systematic reviews

8. Landmark Evidence

9. Controversies

• The prevention-vs-treatment evidence divergence for NPWT is the central, genuinely important tension in this protocol — this protocol explicitly does not extrapolate NPWT's treatment-phase benefit to a presumed prevention-phase benefit, treating these as two separate evidentiary questions with two different (and currently divergent) answers.
• Why prophylactic NPWT might plausibly cause harm rather than simply show no benefit remains incompletely explained — the 2025 propensity-matched finding is striking but based on a single study; this protocol treats it as a genuine reason for caution rather than a definitively proven mechanism of harm, while still taking the signal seriously enough to avoid recommending routine prophylactic use.
• RV rupture as an NPWT complication is a rare but catastrophic, location-specific risk that most general wound-care NPWT literature (developed for extremity/abdominal wounds) does not adequately anticipate — a genuine reason cardiac-surgery-specific protocols and vigilance differ from generic NPWT guidance.

10. References

1. Taghizadeh-Waghefi A, De Angelis V, Bastouni T, et al. Closed-Incision Negative-Pressure Wound Therapy in Bypass Surgery: Evidence and Implications for Personalized Care. J Pers Med. 2025;15(10):448.
2. Effectiveness and safety of negative pressure wound therapy in patients with deep sternal wound infection: a systematic review and meta-analysis. 2024.
3. Comparison of negative pressure wound therapy with conventional wound care in the treatment of sternal wound infection after cardiac surgery: A meta-analysis with trial sequential analysis. PLOS One. 2025.
4. Perezgrovas-Olaria R, Audisio K, Cancelli G, et al. Deep sternal wound infection and mortality in cardiac surgery: a meta-analysis. Ann Thorac Surg. 2023;115(1):272-280.
5. Song Y, Chu W, Sun J, et al. Review on risk factors, classification, and treatment of sternal wound infection. J Cardiothorac Surg. 2023;18:184.
6. Prophylactic Negative Pressure Therapy in Reducing the Risk of Sternal Wound Infection after Cardiac Surgery. 2025.
7. Prevention of the Risk of Complete Sternotomy Scar Dehiscence in Cardiac Surgery: NPWT vs. Standard Dressing. ClinicalTrials.gov NCT06207630.
8. Comparison of Vacuum-Assisted Closure Therapy Versus Conventional Treatment for Post-sternotomy Mediastinitis. 2024.

See also: Postoperative Atrial Fibrillation Prophylaxis After Cardiac Surgery (Cardiovascular System) for the parallel surrogate-vs-clinical-outcome caution (PALACS); Management After Coronary Artery Bypass Grafting (this section) for the general postoperative wound/harvest-site context; Massive Hemorrhage & Coagulopathy After Cardiopulmonary Bypass (this section) for the broader post-CPB complication landscape this protocol adds a specific infectious complication to.

This completes the Cardiac Surgery Critical Care section — all 16 protocols now built at full depth with Quick Recap sections and database entries.